| 05th week of 2021 patent applcation highlights part 28 |
| Patent application number | Title | Published |
|---|
| 20210032568 | POLYALKYLENE GLYCOL-CONTAINING COMPOUND - The present invention provides a polyalkylene glycol-containing compound having higher detergency than conventional polyalkylene glycol-containing compounds. The present invention relates to a polyalkylene glycol-containing compound represented by the following formula (1-1). | 2021-02-04 |
| 20210032569 | 2-ETHYLHEXANOL ETHOXYLATE AS A HYDROTROPE IN LIQUID DETERGENTS - The present disclosure relates to a detergent composition including an alkyl benzyl sulfonate surfactant and ethoxylated 2-ethylhexanol. The composition may be formed by neutralizing a alkylbenzene sulfonic acid with an alkaline solution in the presence of a hydrotrope. | 2021-02-04 |
| 20210032570 | METHODS AND COMPOSITIONS FOR REDUCING PERSISTENT ODOR IN CLOTHING AND MITIGATING BIOFILMS ON VARIOUS MATERIALS - Novel methods and compositions for treating textiles and other materials are disclosed in which persistent odor or other symptoms of biofilm presence can be reduced through the use of compositions comprising N-acetyl cysteine or other agents in combination with certain enzymes. | 2021-02-04 |
| 20210032571 | Corrosion Protection For Glassware In A Dishwasher - A gel which is based on polysaccharide and which includes glass protection additives selected from zinc salts, polyvinyl amide, polyvinyl amine, or combinations thereof. The invention additionally relates to the use of the gel for the corrosion protection of glassware during cleaning and/or rinsing processes, in particular in a dishwasher, and to a method for preventing the corrosion of glassware during cleaning and/or rinsing processes, in particular in a dishwasher. | 2021-02-04 |
| 20210032572 | Foaming Compositions for Producing a Stable Foam and Methods for Making Same - Foaming compositions containing one or more gas bubble-stabilizing agents and an effervescent system such that the foaming compositions create stable foams, foaming products containing such foaming compositions, and methods for making such foaming compositions and foaming products are provided. | 2021-02-04 |
| 20210032573 | PERSONAL PROTECTIVE EQUIPMENT FREE DELIMER COMPOSITIONS - General purpose liquid deliming compositions are disclosed. The compositions include acids, surfactants, and pH modifiers and are adjusted to a pH of 2 to 7. The composition may be used without personal protective wear or transportation restriction and demonstrate similar lime removal to other traditional lime removal compositions which are extremely low in pH and require protective gear by the user. The compositions also do not require the use of chelants, or builders for effective cleaning. Methods of using the deliming compositions are also disclosed. | 2021-02-04 |
| 20210032574 | ANTIMICROBIAL COMPOSITION - An antimicrobial cleaning composition having a pH of from about 9 to about 14 wherein the composition comprises a bispyridinium alkane antimicrobial active and the composition is substantially free of a quaternary ammonium antimicrobial active. | 2021-02-04 |
| 20210032575 | PHOSPHORUS FREE LOW TEMPERATURE WARE WASH DETERGENT FOR REDUCING SCALE BUILD-UP - Phosphorus-free detergent compositions are provided. Detergent compositions including an aminocarboxylate, water conditioning agent, source of alkalinity and water beneficially do not require the use of additional surfactants and/or polymers to provide suitable detergency and prevent scale build-up on treated surfaces. The detergent compositions are used with a sanitizer to employ the phosphorus-free detergent compositions for use as low temperature ware wash detergents that beneficially reduce scale build-up. Methods of employing the phosphorus-free detergent compositions are also provided. | 2021-02-04 |
| 20210032576 | ANTI-VIRAL CLEANING COMPOSITION, METHOD OF MAKING AND USE THEREOF - A method for formulating a cleaning composition contains the step of coating a granular absorbent material with a coating agent to produce a coated absorbent material and mixing the coated absorbent material with a sanitation agent, wherein the coated absorbent material absorbs the sanitation agent to form the cleaning composition. The resulting cleaning composition may be used for cleaning up pathogens or hazardous materials. The cleaning composition may also functions as a liquefiable dry cleaning powder for public areas in response to bodily fluid incidents. A coating method of a non-toxic bio static film on a high surface area solid is disclosed. | 2021-02-04 |
| 20210032577 | CLEANING PRODUCT COMPRISING AN INVERTED CONTAINER ASSEMBLY AND A VISCOUS CLEANING COMPOSITION - The invention relates to a cleaning product including an inverted container assembly comprising an inverted container and a liquid dispenser attached to a bottom surface of the inverted container, and a viscous cleaning composition contained in the inverted container assembly. The present invention also relates to the use of the cleaning product for cleaning dishware. | 2021-02-04 |
| 20210032578 | WIPE WITH A GUANIDINYL-CONTAINING POLYMER - A wipe article includes a substrate, a cationic coating disposed on a surface of the substrate, distributed throughout the substrate, or both. The cationic coating contains a guanidinyl-containing polymer that is crosslinked and bound to the substrate. The substrate includes sponge, nonwoven fabric, or woven fabric. The wipes are useful for removing microorganisms from a microorganism-contaminated surface and also for reducing re-contamination of the cleaned surface or transfer to another surface of the removed microorganisms. | 2021-02-04 |
| 20210032579 | REFINED FERMENTED BEVERAGES, AND A METHOD THEREOF - Methods and systems for making refined fermented beverages, including neutral malt beverages, having reduced or negligible levels of organic acids, particularly acetic acid, relative to bright beer and other untreated fermented beverages. The refined fermented beverages are produced using a caustic dosing system to neutralize naturally-present organic acids typically present in untreated fermented beverages and convert them into their respective conjugate bases as salts. The salts of the neutralized organic acids are then removed or separated from the treated fermented beverage to form the refined fermented beverage. | 2021-02-04 |
| 20210032580 | CELL CULTURE CONTAINER, METHOD FOR MANUFACTURING CELL CULTURE CONTAINER, CELL RECOVERY SYSTEM AND METHOD FOR ACQUIRING CELLS - A cell culture container is provided which is filled with a cell culture substrate ( | 2021-02-04 |
| 20210032581 | ANAEROBIC PHOTOBIOREACTOR AND METHOD FOR BIOMASS CULTIVATION, WASTEWATER TREATMENT, NUTRIENTS RECOVERY, ENERGY PRODUCTION AND HIGH-VALUE PRODUCTS SYNTHESIS - The present invention is related to an anaerobic photobioreactor and a method for active biomass cultivation, wastewater treatment, nutrients recovery, energy production and high-value products synthesis. Phototrophic bacteria are cultured in the anaerobic photobioreactor lighted with solar or artificial irradiation where certain light wavelengths are selectively discarded with a light selector installed on the top of the photobioreactor. In this light-based process wastewater treatment and resources recovery, like nutrients and high-value bioproducts (fertilizers, polymers and proteins) present in wastewater are performed simultaneously. Cultured biomass is treated by anaerobic digestion for biofuel production, including optative hydrolytic pre-treatment, and/or valuable bioproducts can be obtained in a downstream process. | 2021-02-04 |
| 20210032582 | METHOD AND SYSTEM FOR CONVERTING ELECTRICITY INTO ALTERNATIVE ENERGY RESOURCES - A method of using electricity to produce methane includes maintaining a culture comprising living methanogenic microorganisms at a temperature above 50° C. in a reactor having a first chamber and a second chamber separated by a proton permeable barrier, the first chamber comprising a passage between an inlet and an outlet containing at least a porous electrically conductive cathode, the culture, and water, and the second chamber comprising at least an anode. The method also includes coupling electricity to the anode and the cathode, supplying carbon dioxide to the culture in the first chamber, and collecting methane from the culture at the outlet of the first chamber. | 2021-02-04 |
| 20210032583 | ADVANCED TISSUE ENGINEERING SYSTEM - The invention is an automated advanced tissue engineering system that comprises a housing in which one or more tissue engineering modules are accommodated together with a central microprocessor that controls functioning of the tissue engineering modules. In one embodiment, the tissue engineering module comprises a housing supporting one or more bioreactor chamber assemblies and a fluid reservoir operationally engageable with the housing. The bioreactor chamber assemblies may be selected depending on the end product option desired and may include, for example, a cell therapy bioreactor chamber, a single implant bioreactor chamber and a multiple (mosaic) implant bioreactor chamber. | 2021-02-04 |
| 20210032584 | BLOOD VESSEL-MIMICKING MICROFLUIDIC CHIP FOR CELL CO-CULTURE AND USE THEREOF - The present disclosure provides a blood vessel-mimicking microfluidic chip for cell co-culture and a use thereof, wherein the microfluidic chip of the present disclosure is a microfluidic chip capable of co-culturing vascular endothelial cells and cancer cells, and can mimic normal vascular tissue, cancer tissue, and cancer-metastatic vascular tissue, and therefore can be widely used in studies associated with cancer, and especially, is suitable in studies on cancer metastasis, intravenous injection environments for cancer treatment, photothermal therapeutic effects on cancer cell, and the like. | 2021-02-04 |
| 20210032585 | TUBULAR CELL STRUCTURE CULTIVATION MAINTAINING APPARATUS AND TUBULAR CELL STRUCTURE MAINTAINING SUPPORT DEVICE - It is solved by the rod-shaped tubular cell structure maintaining support device for cultivating a tubular cell structure including a hollow portion inside for a predetermined period of time while maintaining the hollow portion, the tubular cell structure maintaining support device including an outer diameter insertable into the hollow portion of the cell structure, and when inserted into the hollow portion, capable of allowing the tubular cell structure maintaining support device to adhere to an inner surface of the cell structure, and a penetration conduit including openings at both ends of the tubular cell structure maintaining support device, and penetrating between the openings, wherein the tubular cell structure maintaining support device has an oxygen permeable structure from the penetration conduit to an outer surface of the tubular cell structure maintaining support device. | 2021-02-04 |
| 20210032586 | BIO-REACTIVE SYSTEM AND METHOD FOR VOLTAGE CONTROLLED METABOLISM - Bio-reactive systems for voltage controlled metabolism are described, that include electrochemical-electrostatic systems having a conventional three electrode cell modified with at least one additional gating electrode. The rate of a metabolic process occurring in at least one organism disposed on a working electrode is controllable by applying a gating voltage VG to the at least one gating electrode. A method for voltage controlled metabolism in a bio-reactive electrostatic cell that includes applying a gating voltage VG to at least one gating electrode is also described. The rate of a metabolic process may he controlled by altering at least one of the magnitude and polarity of the applied gating voltage VG. The method for voltage controlled metabolism may further be used to treat cancer and/or increase the rate of ethanol production by fermentation. | 2021-02-04 |
| 20210032587 | MULTIPLE INCUBATOR CELL CULTURE SYSTEM WITH ATMOSPHERIC REGULATION OPERATED BY AN INTEGRATED CONTROL SYSTEM - Embodiments of a cell culture incubator system provided herein have two or more individual incubators and atmospheric regulation system configured to regulate atmospheric conditions within the environmental chamber of each individual incubator. The atmospheric regulation system has a single integrated controller system that controls atmospheric regulation of each of the individual incubators independently of the one or more other individual incubators. Atmospheric conditions within each of the individual incubators include at least the oxygen level and the total gas pressure, which are regulated independently of each other. | 2021-02-04 |
| 20210032588 | SYSTEMS AND METHODS FOR PARTICLE ANALYSIS - The present disclosure provides systems and methods for sorting a cell. The system may comprise a flow channel configured to transport a cell through the channel. The system may comprise an imaging device configured to capture an image of the cell from a plurality of different angles as the cell is transported through the flow channel. The system may comprise a processor configured to analyze the image using a deep learning algorithm to enable sorting of the cell. | 2021-02-04 |
| 20210032589 | METHODS AND DEVICES FOR THE ISOLATION OF SUBCELLULAR COMPONENTS - One aspect of the invention provides an apparatus for isolating one or more subcellular components including a cell disruption reservoir that generates at least one of a phase change, a thermal change, a physical contact force, an ultrasonic frequency, an osmotic change, a pressure change, a photothermal pulse, a magnetic field, an electromagnetic field, an electric field, and an electrical pulse through the reservoir and a separation instrument configured to specifically isolate the subcellular components based on one or more parameters selected from at least one of density, charge/pH, dielectric polarization, magnetic attraction, spectral dispersion, spectral refraction, spectral diffraction, hydrophobicity, hydrophilicity, structure (presence or absence of a structural feature), function (migration), affinity or binding, and pressure. | 2021-02-04 |
| 20210032590 | METHOD FOR PREPARING AN IRRADIATED PLATELET LYSATE - The invention relates to a method for preparing an irradiated platelet lysate, comprising the steps of providing a starting platelet lysate having platelet factors including growth factors and plasma proteins including coagulation factors and proteins other than the coagulation factors. Double irradiation of the starting platelet lysate, using UVC radiation and ionizing radiation. The double irradiation with UVC radiation and ionizing radiation being arranged to retain at least 75% of the total protein concentration of the starting platelet lysate, while reducing, by at least 40%, the concentration of at least one of the coagulation factors including fibrinogen, factor II, factor VII, factor IX, factor X and factor XI of the starting platelet lysate. | 2021-02-04 |
| 20210032591 | HYPOTHERMIC 3D BIOPRINTING OF LIVING TISSUES SUPPORTED BY PERFUSABLE VASCULATURE - The present disclosure provides compositions and methods for producing hydrogel matrix constructs. Methods of using hydrogel matrix constructs for tissue repair and regeneration and for the oxygenation of red blood cells are also disclosed. | 2021-02-04 |
| 20210032592 | HYPOTHERMIC 3D BIOPRINTING OF LIVING TISSUES SUPPORTED BY PERFUSABLE VASCULATURE - The present disclosure provides compositions and methods for producing hydrogel matrix constructs. Methods of using hydrogel matrix constructs for tissue repair and regeneration and for the oxygenation of red blood cells are also disclosed. | 2021-02-04 |
| 20210032593 | MATURATION OF MAMMALIAN HEPATOCYTES - Directed differentiation and maturation of mammalian hepatocytes, such as human hepatocytes. The hepatocyte obtained show a phenotype which is more similar to that of primary hepatocytes than previously shown. In particular, exposure of mammalian hepatocytes, such as human hepatocytes, to at least one maturation factor selected from the group consisting of Src kinase inhibitors, vitamin D including precursors, metabolites and analogs thereof, hypoxia inducing compounds, sphingosine and sphingosine derivatives, activators of peroxisome proliferator-activated receptors (PPARs), platelet-activating factor (PAF), PKC inhibitors, and combinations thereof. | 2021-02-04 |
| 20210032594 | EXOSOME ACTIVE FORMULATION FOR INHIBITING ENDOTHELIAL CELL MIGRATION, AND PREPARATION METHOD AND APPLICATION - An exosome active formulation for inhibiting endothelial cell migration, and a preparation method and use thereof include the following steps: isolating primary umbilical vein endothelial cells and performing cell culture and passage; adding anisodamine to a culture medium of the subcultured endothelial cells to pretreat the endothelial cells, and then replacing the culture medium with a new endothelial cell culture medium and adding TNF-α to continue the culture of the endothelial cells; extracting exosomes from the TNF-α containing endothelial cell culture medium obtained after the endothelial cells are cultivated; and identifying the exosomes. The exosome active formulation for inhibiting endothelial cell migration prepared by the preparation method of this disclosure and its use in the antitumor drugs. | 2021-02-04 |
| 20210032595 | METHOD FOR RECONSTRUCTING IMMUNE FUNCTION USING PLURIPOTENT STEM CELLS - According to the present invention, there are provided a method for producing a human T cell, which comprises the steps of inducing an iPS cell from a human T cell, and differentiating the iPS cell into a T cell; a pharmaceutical composition comprising the T cell produced by the method; and a method for cell-based immunotherapy using the method. | 2021-02-04 |
| 20210032596 | METHOD OF PRODUCING ERYTHROCYTES - Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perfusate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrable erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place. | 2021-02-04 |
| 20210032597 | METHOD OF PRODUCING NATURAL KILLER CELLS AND COMPOSITION FOR TREATING CANCER - A method for producing natural killer cells is disclosed. The method comprises isolating peripheral blood mononuclear cells (PBMCs) from a blood sample; isolating at least one of CD56+ cells and/or CD3−/CD56+ cells from the PBMCs; and co-culturing the at least one of CD56+ cells and/or CD3−/CD56+ cells with a combination of feeder cells in the presence of a cytokine. A composition for treating cancer is also disclosed. The composition comprises the CD56+ natural killer cells produced by the disclosed method and a cytokine. | 2021-02-04 |
| 20210032598 | ACTIVATION-INDUCED TISSUE-EFFECTOR CELLS SUITABLE FOR CELL THERAPY AND EXTRACELLUAR VESICLES DERIVED THEREFROM - The present invention provides a method of inducing activation of a non-potent or insufficiently potent cell to convert the cell into a tissue-effector cell, thereby producing an activation-induced tissue-effector cell suitable for use in cell therapy—e.g., an activated specialized tissue-effector cell (ASTEC) suitable for cell therapy for a particular tissue type. The present invention further provides activation-induced tissue-effector cells produced thereby, as well as extracellular vesicles, e.g., exosomes, derived therefrom (e.g., ASTEX). The present invention further provides a method of improving the efficacy of a cell therapy by converting non-potent or insufficiently potent cells into activation-induced tissue-effector cells having increased potency suitable for cell therapy. The present invention further provides a method for treating a disease or condition amenable to cell therapy in a subject in need thereof, the method comprising administering a therapeutically effective amount of activation-induced tissue-effector cells or extracellular vesicles derived therefrom. | 2021-02-04 |
| 20210032599 | ENHANCED DIFFERENTIATION OF MESENCHYMAL STEM CELLS - Isolated populations of mesenchymal stem cells (MSCs) are provided, including mammalian mesenchymal stem cells (MSCs) characterized by the lack of CD54 (CD54 | 2021-02-04 |
| 20210032600 | PROGENITOR CELLS OF MESODERMAL LINEAGE - The invention relates to progenitor cells of mesodermal lineage and their use in therapy. | 2021-02-04 |
| 20210032601 | METHOD OF INCREASING PROLIFERATION OF PANCREATIC BETA CELLS, TREATMENT METHOD, AND COMPOSITION - Disclosed herein are methods of increasing cell proliferation in a population of pancreatic beta cells. Also disclosed are methods of treating a subject for a condition associated with insufficient insulin secretion. Also disclosed is a composition comprising a DYRK1 A inhibitor and a GLP1R agonist. The disclosure further describes a method of regenerating pancreatic beta cells in a transplant patient. | 2021-02-04 |
| 20210032602 | EX VIVO PROLIFERATION OF EPITHELIAL CELLS - The technology relates in part to methods and compositions for ex vivo proliferation and expansion of epithelial cells. | 2021-02-04 |
| 20210032603 | PHENAZINE DEGRADING AGENTS AND RELATED COMPOSITIONS, METHODS AND SYSTEMS FOR INTERFERING WITH VIABILITY OF BACTERIA - Provided herein are phenazine degrading agents, methods and systems for interfering with viability of bacteria and related antimicrobial and compositions. | 2021-02-04 |
| 20210032604 | METHODS AND COMPOSITIONS INVOLVING PROMOTERS DERIVED FROM YARROWIA LIPOLYTICA - The current methods and compositions provide for nucleotide sequences of promoters from | 2021-02-04 |
| 20210032605 | BIOCATALYSTS AND METHODS FOR HYDROXYLATION OF CHEMICAL COMPOUNDS - The present invention provides engineered proline hydroxylase polypeptides for the production of hydroxylated compounds, polynucleotides encoding the engineered proline hydroxylases, host cells capable of expressing the engineered proline hydroxylases, and methods of using the engineered proline hydroxylases to prepare compounds useful in the production of active pharmaceutical agents. | 2021-02-04 |
| 20210032606 | DOXA PROTEIN MUTANT, AND CODING GENE AND APPLICATIONS THEREOF - The present invention relates to a DoxA protein mutant having an amino acid sequence set forth in SEQ ID No. 16, and coding gene thereof. The protein mutant or the coding gene thereof can be used for producing epirubicin. The present invention further relates to a | 2021-02-04 |
| 20210032607 | SOLUBLE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGR3) POLYPEPTIDE FOR USE IN THE PREVENTION OR TREATMENT OF SKELETAL GROWTH RETARDATION DISORDERS - The present invention relates to the prevention or treatment of skeletal growth retardation disorders, in particular skeletal diseases, developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FG-FR3), in particular by expression of a constitutively activated mutant of FGFR3. More particularly, the present invention relates to a soluble FGFR3 for use in the prevention or treatment of achondroplasia. | 2021-02-04 |
| 20210032608 | SOLUBLE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGR3) POLYPEPTIDE FOR USE IN THE PREVENTION OR TREATMENT OF SKELETAL GROWTH RETARDATION DISORDERS - The present invention relates to the prevention or treatment of skeletal growth retardation disorders, in particular skeletal diseases, developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FG-FR3), in particular by expression of a prolonged activated mutant of FGFR3. More particularly, the present invention relates to a soluble FGFR3 for use in the prevention or treatment of achondroplasia. | 2021-02-04 |
| 20210032609 | DNA POLYMERASES FOR EFFICIENT AND EFFECTIVE INCORPORATION OF METHYLATED-DNTPS - Disclosed are DNA polymerases having improved ability to incorporate methylated-dNTPs, relative to a corresponding, unmodified polymerase. The polymerases are useful in a variety of disclosed primer extension methods. Also disclosed are related compositions, including recombinant nucleic acids, vectors, and host cells, which are useful, e.g., for production of the DNA polymerases. Further disclosed are kits and reaction mixtures comprising the improved DNA polymerases as well as methods of primer extension using the improved DNA polymerases. | 2021-02-04 |
| 20210032610 | Compositions for Treating Ectopic Calcification Disorders, and Methods Using Same - The present invention includes compositions and methods for treating disease and disorders associated with pathological calcification or pathological ossification. | 2021-02-04 |
| 20210032611 | Angiogenin Expression in Plants - The present invention relates to plant-produced angiogenins, to related plant cells, plant calli, plants, seeds and other plant parts and products derived therefrom and to uses of plant-produced angiogenins. The present invention also relates to expression of angiogenin genes in plants and to related nucleic acids, constructs and methods. | 2021-02-04 |
| 20210032612 | CRISPR/Cas9 Systems, and Methods of Use Thereof - The present disclosure relates to Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR associated protein 9 (Cas9) systems, and methods of use thereof for gene editing or for preventing, ameliorating or treating a disease associated with a gene mutation or single-nucleotide polymorphism (SNP) in a subject. | 2021-02-04 |
| 20210032613 | SIMULTANEOUS MULTIPLEX GENOME EDITING IN YEAST - The present disclosure provides compositions of matter, methods and instruments for editing nucleic acids in live yeast cells. | 2021-02-04 |
| 20210032614 | FUNGAL POLYPEPTIDES HAVING LYSOZYME ACTIVITY - The present invention relates to novel lysozyme enzymes from the genus of | 2021-02-04 |
| 20210032615 | LACTASE ENZYMES WITH IMPROVED PROPERTIES - The present invention relates to new improved peptides and dimeric peptides exhibiting beta-galactosidase enzyme activity as well as methods using them for reducing the lactose content of milk-based compositions. | 2021-02-04 |
| 20210032616 | FACTOR IX FUSION PROTEINS AND METHODS OF MAKING AND USING SAME - The present invention provides Factor IX (FIX) fusion proteins comprising at least one heterologous moiety, such as an XTEN. The present invention further discloses methods of making and using the FIX fusion proteins. | 2021-02-04 |
| 20210032617 | MODIFIED MEMBRANE TYPE SERINE PROTEASE 1 (MTSP-1) POLYPEPTIDES AND METHODS OF USE - Provided are MTSP-1 polypeptides modified to have altered activity and/or specificity so that they cleave a complement protein, such as complement protein C3, to inhibit its activity and thereby inhibit complement activation. The modified MTSP-1 polypeptides that inhibit complement activation can be used for treatment of diseases and conditions in which complement activation plays a role. Such diseases and conditions include inflammatory diseases and diseases with an inflammatory component. Exemplary of these disorders are ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, ophthalmic disorders, such as diabetic retinopathies and macular degeneration, including age-related macular degeneration (AMD), and transplanted organ rejection, such as renal delayed graft function (DGF). | 2021-02-04 |
| 20210032618 | COMBINED LYSIS PROTOCOL FOR COMPREHENSIVE CELL LYSIS - Disclosed are methods for lysis of cells, such as bacteria present in microbiomes, that combine three lysis steps—(1) heat, (2) detergent and (3) base—into a single step and that can be completed in a short period of time, e.g., a few minutes. The methods combine a normally incompatible detergent and base lysis, allows for simplified removal of detergent after lysis, and importantly, yields improved quantities of genomic DNA (gDNA) from difficult to lyse bacteria. | 2021-02-04 |
| 20210032619 | VECTOR LIBRARY FOR YEAST TWO HYBRID SCREENING AND METHOD FOR IDENTIFYING DEUBIQUITINATING ENZYME BINDING TO TARGET PROTEIN USING SAME - The present invention provides a vector library for yeast two-hybrid screening of a deubiquitinating enzyme that binds to a target protein and a method for identifying a deubiquitinating enzyme binding to a target protein using the same. Also, the present invention provides a method for screening an agent having anti-cancer activity targeting the deubiquitinating enzyme USP1, USP7, USP12, or USP49 identified by said identifying method. | 2021-02-04 |
| 20210032620 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF - Among other things, the present disclosure provides oligonucleotides, compositions, and methods thereof. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., knockdown ability, stability, delivery, etc. In some embodiments, the oligonucleotides decrease the expression, activity and/or level of a C9orf72 gene, including but not limited to, one comprising a repeat expansion, or a gene product thereof. In some embodiments, the present disclosure provides methods for treatment of diseases using provided oligonucleotide compositions, for example, in treatment of C9orf72-related disorders. | 2021-02-04 |
| 20210032621 | EXTENDED SINGLE GUIDE RNA AND USE THEREOF - The present disclosure relates to: an extended guide RNA and a composition for base editing, comprising the same; and a method for base editing and a method for producing genetically modified animals or plants, both methods using the composition for base editing. | 2021-02-04 |
| 20210032622 | SELF-INACTIVATING (SIN) CRISPR/CAS OR CRISPR/CPF1 SYSTEMS AND USES THEREOF - The invention relates to self-inactivating/self-targeting CRISPR/Cas or CRISPR/Cpf1 systems. The invention also relates to genetically modified cells related to the same. The invention also relates to methods of controlling Cas9 expression in a cell related to the same. The invention also relates to methods of genetically modifying a cell related to the same. The invention also relates to nucleic acids for use in a self-inactivating CRISPR/Cas or CRISPR/Cpf1 system. The invention also relates to pharmaceutical compositions related to the same. | 2021-02-04 |
| 20210032623 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, PREPARATION METHOD THEREFOR AND USE THEREOF - Provided are a siRNA for inhibiting the expression of an angiopoietin-like protein 3 (ANGPTL3) gene, and a pharmaceutical composition and a conjugate comprising the siRNA; wherein each nucleotide in the siRNA is independently a modified or unmodified nucleotide, and the siRNA comprises a sense strand and an antisense strand; the sense strand comprises a nucleotide sequence A, the nucleotide sequence A having the same length as the nucleotide sequence as represented by SEQ ID NO:1 with no more than 3 nucleotide differences; the antisense strand comprises a nucleotide sequence B, the nucleotide sequence B having the same length as the nucleotide sequence as represented by SEQ ID NO:2 with no more than 3 nucleotide differences. | 2021-02-04 |
| 20210032624 | Compositions and Methods for Modulation of SMN2 Splicing in a Subject - Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. | 2021-02-04 |
| 20210032625 | TRANSGENIC MICROALGAE AND USE THEREOF AS A FEED FOR DELIVERY OF INTERFERING RNA MOLECULES - The present invention provides non-propagating transgenic microalgae expressing at least one heterologous RNAi molecule. The RNAi-expressing non-propagating transgenic microalgae are used for oral delivery of the RNAi molecule to a target organism in its intact and functional form. The heterologous RNAi molecule, present within the microalgae, is characterized by being biologically active, exerting at least one specific effect on the organism consuming the microalgae or on a pathogen of said organism. In particular, the non-propagating transgenic microalgae are used as agents for biological control of animal and plant pests. | 2021-02-04 |
| 20210032626 | Material for capturing circulating cells in the blood, method of preparation and use - A material chosen from alumina ceramic grafted with at least one aptamer, at least one antibody or their combination for capturing circulating foreign cells, preferably circulating tumor cells, the method of preparing such material, its use and the device comprising it are disclosed. | 2021-02-04 |
| 20210032627 | GENE THERAPEUTIC FOR THE TREATMENT OF HIV AND USES THEREOF - The present disclosure provides for an expression vector comprising (i) at least one nucleic acid sequence encoding a transcriptional gene silencing element; and (ii) at least two other nucleic acid sequences selected from the group consisting of a nucleic acid sequence that encodes a nucleic acid molecule that inhibits an HIV co-receptor; a nucleic acid sequence that encodes an HIV fusion inhibitor protein; a nucleic acid sequence encoding an inhibitor of HIV replication; and a nucleic acid sequence encoding an inhibitor of viral entry. The combination of the three mechanisms in a single expression vector provides for novel means of inhibiting HIV-1. | 2021-02-04 |
| 20210032628 | DOUBLE-HELIX OLIGONUCLEOTIDE CONSTRUCT COMPRISING DOUBLE-STRANDED MIRNA AND USE THEREOF - The present invention relates to a double-helix oligonucleotide construct comprising a double-stranded miRNA and a composition for preventing or treating cancer comprising the same. More particularly, the present invention relates to a double-helix oligonucleotide construct comprising miR-544a characterized by a method that effectively inhibits the proliferation of cancer cells or induces a voluntary death of cancer cells, and an anticancer composition comprising the construct. | 2021-02-04 |
| 20210032629 | OLIGONUCLEOTIDE THERAPY FOR WILSON DISEASE - The present disclosure provides antisense oligonucleotides, compositions, and methods that target ATP7B exon 6 or a flanking intron, thereby modulating splicing of ATP7B pre-mRNA to increase the level of ATP7B mRNA molecules having exon 6, e.g., to provide a therapy for Wilson disease. The present disclosure provides an antisense oligonucleotide including a nucleobase sequence at least 70% complementary to an ATP7B target sequence in exon 6, a 5′-flanking intron, a 3′-flanking intron, or a combination of exon 6 and the 5′-flanking or 3′-flanking intron. | 2021-02-04 |
| 20210032630 | Composition for Suppressing Inflammation - The disclosure provides a composition for suppressing inflammation comprising at least one substance that disrupts a stem-loop structure in the 3′ untranslated region of a Regnase-1 mRNA, wherein the stem-loop structure is at least one stem-loop structure selected from a first stem-loop structure formed in a region corresponding to positions 231 to 245 of SEQ ID NO: 1 and a second stem-loop structure formed in a region corresponding to positions 424 to 442 of SEQ ID NO: 1. | 2021-02-04 |
| 20210032631 | Compositions and Methods for Correcting Limb Girdle Muscular Dystrophy Type 2C Using Exon Skipping - The invention is directed to one or more antisense polynucleotides and their use in pharmaceutical compositions in a strategy to induce exon skipping in the γ-sarcoglycan gene in patients suffering from Limb-Girdle Muscular Dystrophy-2C (LGMD2C) or in patients at risk of such a disease. The invention also provides methods of preventing or treating muscular dystrophy, e.g., LGMD2C, by exon skipping in the gamma sarcoglycan gene using antisense polynucleotides. Accordingly, in some aspects the invention provides an isolated antisense oligonucleotide, wherein the oligonucleotide specifically hybridizes to an exon target region of a γ-sarcoglycan RNA. In another aspect, the the invention provides a method of inducing exon-skipping of a gamma sarcoglycan RNA, comprising delivering an antisense oligonucleotide or a composition to a cell. | 2021-02-04 |
| 20210032632 | MATERIALS AND METHODS FOR THE BIOSYNTHESIS OF SEVEN CARBON CHEMICALS IN THE PRESENCE OF METHANOL OXIDATION - This disclosure describes methods for regulating the biosynthesis of pimelic acid, 7-aminoheptanoate, 7-hydroxyheptanoate, heptamethylenediamine, 7-aminoheptanol, or 1,7-heptanediol by channeling increased flux through the biosynthesis pathway to obtain an intermediate required for growth of the host microorganism. | 2021-02-04 |
| 20210032633 | DRUG FOR CHRONIC INFLAMMATORY DISEASE AND METHOD FOR EVALUATING SUSCEPTIBILITY TO CHRONIC INFLAMMATORY DISEASE - [Problem] The purpose of the present invention is to provide new treatment targets and treatment methods for chronic inflammatory disease based on a molecular biological mechanism relating to the onset of keloid. [Solution] The present invention relates to a drug for the prevention and/or treatment of chronic inflammatory disease that contains as an active ingredient a substance that suppresses the expression and/or inhibits the activity of a specific NEDD4 splicing variant protein. Also provided are a method for evaluating the susceptibility of a subject to chronic inflammatory disease and a method for evaluating the suitability of treatment of a chronic inflammatory disease by the abovementioned drug that include a step for detecting the NEDD4 splicing variant protein or mRNA in a collected tissue, a drug for preventing and/or treating chronic inflammatory disease that contains as an active ingredient a substance that suppresses the expression and/or inhibits the activity of NEDD4 protein, and a method for evaluating the susceptibility of a subject to chronic inflammatory disease that includes a step for detecting a specific SNP of NEDD4. | 2021-02-04 |
| 20210032634 | HUMAN ALZHEIMER'S DISEASE AND TRAUMATIC BRAIN INJURY ASSOCIATED TAU VARIANTS AS BIOMARKERS AND METHODS OF USE THEREOF - The present invention provides detection reagents and method for determining risk of traumatic brain injury (TBI) and/or susceptibility to neurodegenerative disease in a subject. | 2021-02-04 |
| 20210032635 | MODULAR DNA ASSEMBLY SYSTEM - A modular and hierarchical DNA assembly platform for synthetic biology is described. This enabling technology, termed MIDAS (for Modular Idempotent DNA Assembly System), can precisely assemble multiple DNA fragments in a single reaction using a standardised assembly design. It can be used to build genes from libraries of sequence-verified, reusable parts and to assemble multiple genes in a single vector. We describe the design and use of MIDAS, and its application in the reconstruction of the metabolic pathway for production of paspaline, a key intermediate in the biosynthesis of a range of indole diterpenes—a class of economically important secondary metabolites produced by several species of filamentous fungi. | 2021-02-04 |
| 20210032636 | PROMOTER AND USE THEREOF - An improved promoter and a use thereof. An improvement is to mutate a nucleic acid sequence between −35 region and −10 region in a promoter region into recognition sites for an endonuclease. The improvement is used for overcoming the problem that a transcription or translation product of foreign genes under a strong promoter might be toxic to a host and cannot be cloned and avoiding the phenomena of false positives and false negatives during blue-white screening. | 2021-02-04 |
| 20210032637 | EXPRESSION OF PHYTASE IN ASPERGILLUS NIGER - Disclosed herein is a method for expressing phytase in a filamentous fungus by using an optimized | 2021-02-04 |
| 20210032638 | PLASMID CURING - A conjugative recombinant vector is provided for displacing a target plasmid from a host cell. The vector is capable of replicating in the host cell, and is adapted to compete with and/or inhibit replication of the target plasmid. Also provided are systems, cells, compositions and kits comprising the vector. The invention finds use in the displacement of target plasmids such as those carrying antibiotic resistance genes, and in methods of treating bacterial infections. | 2021-02-04 |
| 20210032639 | MODIFIED 5'-UNTRANSLATED REGION (UTR) SEQUENCES FOR INCREASED PROTEIN PRODUCTION IN BACILLUS - The present disclosure is generally modified | 2021-02-04 |
| 20210032640 | METHOD FOR PRODUCTION OF RECOMBINANT ERWINIA ASPARAGINASE - Provided herein are methods of production of recombinant | 2021-02-04 |
| 20210032641 | SYSTEMS AND METHODS FOR UNTARGETED METABOLOMIC SCREENING - Provided herein are systems and methods for untargeted screening of metabolite products of biosynthetic gene clusters. In particular, systems and methods are provided for the detection of secondary metabolites and the correlation off such metabolites to the biosynthetic gene clusters responsible for the biosynthesis thereof. | 2021-02-04 |
| 20210032642 | INCREASED ALCOHOL PRODUCTION FROM YEAST PRODUCING AN INCREASED AMOUNT OF ACTIVE HAC1 PROTEIN - Described are compositions and methods relate to modified yeast that produces an increased amount of active HAC1 transcriptional activator involved in the unfolded protein response pathway. Such yeast is well suited for use in fuel alcohol production to increase yield. | 2021-02-04 |
| 20210032643 | YEAST PROMOTORS FOR PROTEIN EXPRESSION - Isolated nucleic acids, expression methods, host cells, expression vectors, and DNA constructs for producing proteins, and proteins produced using the expression methods are disclosed. More specifically, nucleic acids isolated from | 2021-02-04 |
| 20210032644 | METHOD FOR INTRODUCING SUBSTANCE INTO PLANT CELL - The present invention relates to a method for introducing a substance into a plant cell. The method of the present invention comprises introducing a substance into a plant cell present in the liquid phase using the particle gun method. | 2021-02-04 |
| 20210032645 | TARGETED RECOMBINATION BETWEEN HOMOLOGOUS CHROMOSOMES AND USES THEREOF - Methods of targeted recombination between homologous chromosomes in the genome of a somatic plant cell are described herein, wherein the target site may be located within a region of euchromatin or a region of heterochromatin. These methods may be used to induce a somatic plant cell into using targeted recombination between homologous chromosomes leading to targeted crossover or gene conversion. Methods described utilize a preselected endogenous target site at a locus having polymorphic alleles on the homologous chromosomes. Target site loci disclosed include those within euchromatin and heterochromatin. | 2021-02-04 |
| 20210032646 | METHODS AND COMPOSITIONS FOR INCREASING HARVESTABLE YIELD VIA EDITING GA20 OXIDASE GENES TO GENERATE SHORT STATURE PLANTS - The present disclosure provides compositions and methods for the editing or mutating of specific subtypes of GA20 oxidase genes and specific zygosity combinations of those edits or mutations. Modified plants, and plant parts and cells thereof, having mutations reducing the expression or activity of GA20 oxidase genes are further provided with improved characteristics, such as reduced plant height and increased lodging resistance, but without off-types. Methods are further provided for making modified plants, and plant parts and cells thereof, having one or more mutations in specific subtypes of GA20 oxidase genes. | 2021-02-04 |
| 20210032647 | Genes and uses for plant enhancement - Transgenic seed for crops with enhanced agronomic traits are provided by trait-improving recombinant DNA in the nucleus of cells of the seed where plants grown from such transgenic seed exhibit one or more enhanced traits as compared to a control plant. Of particular interest are transgenic plants that have increased yield. The present invention also provides recombinant DNA molecules for expression of a protein, and recombinant DNA molecules for suppression of a protein. | 2021-02-04 |
| 20210032648 | METHOD FOR IMPROVING SENSITIVITY OF PLANT TO GIBBERELLIN INHIBITOR AND USE THEREOF - The present invention discloses a method for increasing the sensitivity of a plant to a gibberellin inhibitor. The method for increasing the sensitivity of a plant to a gibberellin inhibitor provided by the present invention comprises the step of introducing an encoding gene of a protein into a recipient plant to obtain a transgenic plant; the transgenic plant has increased sensitivity to the gibberellin inhibitor compared to the recipient plant; the protein is a protein of the following a) or b) or c): a) a protein whose amino acid sequence is set forth in positions 1-821 of SEQ ID NO: 1: b) a protein whose amino acid sequence is set forth in SEQ ID NO: 1; c) a fusion protein obtained by attaching tag(s) to the N-terminus or/and C-terminus of a) or b). The experiments prove that the method for increasing the sensitivity of a plant to a gibberellin inhibitor of the present invention can be used to increase the sensitivity of plants to gibberellin inhibitors, and the plant height of plants can be regulated by the plant height-related protein HRP of the present invention. | 2021-02-04 |
| 20210032649 | METHODS AND COMPOSITIONS FOR SHORT STATURE PLANTS THROUGH MANIPULATION OF GIBBERELLIN METABOLISM TO INCREASE HARVESTABLE YIELD - The present disclosure provides compositions and methods for altering gibberellin (GA) content in corn or other cereal plants. Methods and compositions are also provided for altering the expression of genes related to gibberellin biosynthesis through suppression, mutagenesis and/or editing of specific subtypes of GA20 or GA3 oxidase genes. Modified plant cells and plants having a suppression element or mutation reducing the expression or activity of a GA oxidase gene are further provided comprising reduced gibberellin levels and improved characteristics, such as reduced plant height and increased lodging resistance, but without off-types. | 2021-02-04 |
| 20210032650 | SYSTEMS AND METHODS FOR ENHANCING TRICHOME FORMATION AND DENSITY IN CANNABIS - The present invention includes systems, methods and compositions for increasing trichome formation and/or density in cannabinoid producing plants, such as | 2021-02-04 |
| 20210032651 | IMPROVEMENT OF HERBICIDE TOLERANCE TO HPPD INHIBITORS BY DOWN-REGULATION OF PUTATIVE 4-HYDROXYPHENYLPYRUVATE REDUCTASES IN SOYBEAN - A method for conferring tolerance to a 4-hydroxyphenylpyruvate dioxygenase (HPPD) inhibitor herbicide in a plant, comprising reducing expression of at least one 4-hydroxyphenylpyruvate reductase (HPPR) enzyme in the plant. | 2021-02-04 |
| 20210032652 | Wheat Having Resistance to Glyphosate Due to Alterations in 5-Enol-Pyruvylshikimate-3 Phosphate Synthase - Plants with resistance to glyphosate are disclosed herein. In one embodiment, the disclosure relate to human induced non-transgenic mutations in the EPSPS gene in plants. | 2021-02-04 |
| 20210032653 | COMPOSITIONS AND METHODS FOR IMPROVING CROP YIELDS THROUGH TRAIT STACKING - The present disclosure provides modified, transgenic, or genome edited/mutated corn plants that are semi-dwarf and have one or more improved ear traits relative to a control plant, such as increase in ear fresh weight, ear area, ear volume, ear diameter, ear length, ear tip void, number of kernels per ear, single kernel weight, and yield. The modified, transgenic, or genome edited/mutated corn plants comprise a transgene encoding one or more glutamate dehydrogenase (GDH) polypeptides and have a reduced expression of one or more GA20 or GA3 oxidase genes. Also provided are methods for producing the modified, transgenic, or genome edited/mutated corn plants. | 2021-02-04 |
| 20210032654 | RNA-GUIDED GENE EDITING AND GENE REGULATION - Disclosed herein are Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated (Cas) 9-based system related compositions and methods of using said CRISPR/Cas9-based system related compositions for altering gene expression and genome engineering. Also disclosed herein are compositions and methods of using said compositions for altering gene expression and genome engineering in muscle, such as skeletal muscle and cardiac muscle. | 2021-02-04 |
| 20210032655 | ENGINEERED CYTOLYTIC IMMUNECELL - The present invention relates to engineered a cytolytic immune cell comprising: i) a releasable protein which comprises a polypeptide of interest (POI) and a first interaction domain; and ii) a retention protein which is retained within an intracellular compartment of the cell and comprises a second interaction domain which binds to the first protein interaction domain, wherein binding between the first protein interaction domain and second protein interaction domain is disrupted by the presence of an agent, such that in the absence of the agent, the first protein interaction domain and second protein interaction domain bind and result in retention of the POI within an intracellular compartment; whereas in the presence of the agent, the first protein interaction domain and second protein interaction do not bind and the POI is released from the intracellular compartment and expressed at the cell surface or secreted by the cell. | 2021-02-04 |
| 20210032656 | AAV-VECTORS FOR USE IN GENE THERAPY OF CHOROIDEREMIA - The present invention relates to gene therapy for treatment or prevention of choroideremia. | 2021-02-04 |
| 20210032657 | SYNTHETIC GENETIC ELEMENTS FOR BIOMANUFACTURE - Recombinant constructs, cells and means for improved production of Adeno-Associated Viruses (AAVs) are described. Also described are methods of using the constructs and cells to produce recombinant AAVs. | 2021-02-04 |
| 20210032658 | MND PROMOTER CHIMERIC ANTIGEN RECEPTORS - The invention provides vector compositions for delivering improved adoptive T cell therapies. | 2021-02-04 |
| 20210032659 | CARDIAC CELL REPROGRAMMING WITH MYOCARDIN AND ASCL1 - The present disclosure provides methods for generating induced cardiomyocytes and/or inducing a cardiomyocyte phenotype in cells in vivo or in vitro, such as by expression of ASCL1 or MYF6 and MYOCD. The present disclosure further provides gene-delivery vectors comprising one or more polynucleotides selected from ASCL1, MYF6, MYOCD, MEF2C, and TBX5. It further provides compositions comprising induced cardiomyocytes and provides methods of treating a heart condition, such as myocardial infarction. The disclosure also provides engineered myocardin proteins with an internal deletion, vectors encoding such engineered mycocardins, and methods of use thereof. | 2021-02-04 |
| 20210032660 | LIVER TROPIC RECOMBINANT AAV6 VECTORS THAT EVADE NEUTRALIZATION - As demonstrated herein, a modified recombinant AAV6 vector is provided that transduces the liver and has reduced neutralization of transduction of liver by ADK6 antibody. Accordingly, embodiments of the invention relate to liver tropic rAAV6 vectors that evade neutralization. | 2021-02-04 |
| 20210032661 | Methods And Compositions Comprising A Viral Vector For Expression Of A Transgene And An Effector - The present invention relates to compositions and methods comprising a single viral vector comprising both a first polynucleotide comprising a constitutive promoter operably linked to a nucleic acid encoding at least one transgene, wherein one of the at least one transgenes encodes a receptor or receptor subunit, a receptor fusion protein or a fluorescent marker; and a second polynucleotide comprising an inducible promoter operably linked to a nucleic acid encoding an effector. Also provided are engineered cells comprising the viral vector and methods for generating the engineered cells comprising the viral vector. Also provided is site-specific integration of the genetic element into the a gene locus by means of a CRISPR-related system. Further provided are methods for treating a patient having a disease, a disorder or condition associated with expression of an antigen, the method comprising administering to the patient an effective amount of a composition comprising the engineered cell. | 2021-02-04 |
| 20210032662 | MICRORNA-BASED COMPOSITIONS AND METHODS USED IN DISEASE TREATMENT - The present disclosure provides a miRNA hairpin that, when processed by a virus-infected cell, increases the therapeutic effectiveness of the virus. The present disclosure also provides a virus encoding such a miRNA hairpin. The present disclosure also provides pre-miRNAs that, when processed by a virus-infected cell, increase extracellular vesicle secretion of the encoded miRNA hairpin by the virus-infected cell. | 2021-02-04 |
| 20210032663 | DIFFERENTIAL KNOCKOUT OF AN ALLELE OF A HETEROZYGOUS APOLIPOPROTEIN A1 (APO1A) GENE - RNA molecules comprising a guide sequence portion having 17-20 nucleotides in the sequence of 17-20 contiguous nucleotides set forth in any one of SEQ ID NOs: 1-1313 and compositions, methods, and uses thereof. | 2021-02-04 |
| 20210032664 | ENGINEERED MEGANUCLEASES WITH RECOGNITION SEQUENCES FOUND IN THE HUMAN BETA-2 MICROGLOBULIN GENE - Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human beta-2 microglobulin gene. The disclosure further relates to the use of such recombinant meganucleases in methods for producing genetically-modified eukaryotic cells, and to a population of genetically-modified T cells having reduced cell-surface expression of beta-2 microglobulin. | 2021-02-04 |
| 20210032665 | RECOMBINANT YEAST STRAIN FOR PRODUCING NERVONIC ACIDS AND APPLICATION THEREOF - The present invention discloses an engineering yeast strain for producing nervonic acids. The yeast strain over-expresses the genes related to enzymes required in a synthetic process of long-chain unsaturated fatty acids, such as fatty acid elongase, desaturase, diacylglycerol acyltransferase and the like, and optionally, further adjusts and controls the synthesis and decomposition route of triglyceride, the synthesis and decomposition route of sphingomyelin, and the synthesis and decomposition route and the oxidation-reduction balanced route of lipid subcell levels. The recombinant yeast strain can produce microorganism oil; and the content of the prepared nervonic acids accounts for 39.6% of the total fatty acids. | 2021-02-04 |
| 20210032666 | METHOD FOR PRODUCING COENZYME Q10 - Methods for stably producing coenzyme Q10 are provided, which efficiently remove impurities derived from a microorganism in an extract of a coenzyme Q10-producing microorganism. A method for producing coenzyme Q10 includes: cooling a hydrophobic organic solvent extract of a coenzyme Q10-producing microorganism or a concentrated liquid of the hydrophobic organic solvent extract; and separating/removing the solid precipitated in the cooling step, wherein the hydrophobic organic solvent extract or the concentrated liquid has a water content of 50 ppm by weight or more and 1% by weight or less. Preferably, the extract obtained by extraction from a coenzyme Q10-producing microorganism in an organic solvent is brought into contact and mixed with an aqueous alkaline solution and then washed with water, where a resulting extract is concentrated to obtain the concentrated liquid, and the concentrated liquid is subjected to the cooling step. | 2021-02-04 |
| 20210032667 | RECOMBINANT MICROORGANISM FOR IMPROVED PRODUCTION OF ALANINE - The present invention relates to a recombinant nucleic acid molecule, a recombinant microorganism, to a method for producing alanine and to the use of the recombinant nucleic acid molecule or the recombinant microorganism for the fermentative production of alanine. | 2021-02-04 |
